Skip to main content

Research Repository

Advanced Search

All Outputs (75)

Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors (2025)
Journal Article
Molica, S., & Allsup, D. (2025). Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors. Cancers, 17(1), Article 119. https://doi.org/10.3390/cancers17010119

Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a shift from historical chemotherapeutic regimens to targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors. These advancements have been as... Read More about Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.

PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation (2024)
Journal Article
Naylor-Adamson, L., Price, T. W., Booth, Z., Leonard, S. V. L., Gallo, J., Tung, L. D., Harvell-Smith, S., Thi Kim Thanh, N., Aslam, Z., Allsup, D., Hondow, N., Chamberlain, T., Schneider, J. E., Naseem, K., Bouillard, J. S. G., Stasiuk, G. J., & Calaminus, S. D. (in press). PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation. Journal of Materials Chemistry B, https://doi.org/10.1039/d4tb01334d

Quantum dots (QDs) are semiconducting inorganic nanocrystals, that have garnered interest in biological and medical spheres due, to their potential benefits in biomedical imaging and drug-delivery systems. Indium phosphide QDs shelled with zinc sulph... Read More about PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation.

High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition (2024)
Journal Article
James, D., Green, S., Molica, S., & Allsup, D. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. Case Reports in Hematology, 2024, Article 1813512. https://doi.org/10.1155/2024/1813512

The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecu... Read More about High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study (2024)
Presentation / Conference Contribution
C, T., Minga, E., Karakatsoulis, G., Albi, E., Alcoceba, M., Allsup, D., Bacchiarri, F., Besikli-Dimou, S., Chatzileontiadou, S., Collado, R., Davis, Z., Dimou, M., Donaldson, D., Efstathopoulou, M., Galimberti, S., Galitzia, A., Gimeno, E., Guarente, V., Hatzimichael, E., Hernandez-Rivas, J.-A., …Scarfo, L. (2024, December). Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study. Presented at American Society of Hematology 66th Annual Meeting, San Diego, California

Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia (2024)
Journal Article
Molica, S., Allsup, D., & Giannarelli, D. (online). Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia. American Journal of Hematology, https://doi.org/10.1002/ajh.27437

The emergence of Bruton's tyrosine kinase (BTK) inhibitors marked a significant advancement in chronic lymphocytic leukemia (CLL) management, especially for high-risk patients. 1 Ibrutinib, the pioneering BTK inhibitor, has undergone extensive study.... Read More about Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.

Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial (2024)
Journal Article
Flett, L., Abdelatif, R., Akhtar Baz, S., Brady, S., Corbacho, B., Common, K., Cowling, A., Fairhurst, C., Fitzmaurice, E., Gandhi, S., Hilton, A., Hope, W., Howard, A., Laycock, J., Lillie, P., Mitchell, G., Parker, A., Peel, M., Sheard, L., Sneddon, J., …Barlow, G. (2024). Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial. Trials, 25(1), Article 427. https://doi.org/10.1186/s13063-024-08272-w

BACKGROUND: Acute leukaemias (AL) are life-threatening blood cancers that can be potentially cured with treatment involving myelosuppressive, multiagent, intensive chemotherapy (IC). However, such treatment is associated with a risk of serious infect... Read More about Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia—a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population (2024)
Journal Article
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), Article 1085. https://doi.org/10.3390/cancers16061085

To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general populat... Read More about Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population.

How can we optimize antifungal use and stewardship in the treatment of acute leukemia? (2024)
Journal Article
Taynton, T., Allsup, D., & Barlow, G. (2024). How can we optimize antifungal use and stewardship in the treatment of acute leukemia?. Expert Review of Hematology, https://doi.org/10.1080/17474086.2024.2383401

Introduction: The global need for antifungal stewardship is driven by spreading antimicrobial and antifungal resistance. Triazoles are the only oral and relatively well-tolerated class of antifungal medications, and usage is associated with acquired... Read More about How can we optimize antifungal use and stewardship in the treatment of acute leukemia?.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets (2023)
Journal Article
Gil, H. M., Booth, Z., Price, T. W., Lee, J., Naylor‐Adamson, L., Avery, M., Muravitskaya, A., Hondow, N., Allsup, D., Schneider, J. E., Naseem, K., Adawi, A. M., Bouillard, J. S. G., Chamberlain, T. W., Calaminus, S. D., & Stasiuk, G. J. (in press). Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. Small, Article 2304881. https://doi.org/10.1002/smll.202304881

InP/ZnS quantum dots (QDs) have received a large focus in recent years as a safer alternative to heavy metal-based QDs. Given their intrinsic fluorescent imaging capabilities, these QDs can be potentially relevant for in vivo platelet imaging. The In... Read More about Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study (2023)
Presentation / Conference Contribution
Hillmen, P., Cairns, D. A., Bloor, A. J. C., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J. G., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Howard, D., Hockaday, A., Jackson, S., …Munir, T. Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA

Introduction: Ibrutinib (I), an irreversible Btk inhibitor, and venetoclax (V), a Bcl-2 inhibitor, improve CLL outcomes in trials compared to chemoimmunotherapy. I and V target two key pathophysiological pathways in CLL and should be synergistic. Thi... Read More about Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study.

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients (2023)
Presentation / Conference Contribution
Sarma, A., Evans, C., Dalal, S., Webster, N., Rawstron, A., Shingles, J., Newton, D., Cairns, D. A., Glover, P., Grand, T., Warren, H., Bell, S., Girvan, S., Greatorex, N., Hockaday, A., Jackson, S., Phillips, D., Stones, D., Allsup, D., Bloor, A. J. C., …Hillmen, P. Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients. Presented at 65th ASH Annual Meeting And Exposition, San Diego, CA

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial (2023)
Presentation / Conference Contribution
Rawstron, A., Webster, N., Dalal, S., de Tute, R. M., Bell, S., Cairns, D. A., Girvan, S., Greatorex, N., Hockaday, A., Jackson, S., Phillips, D., Stones, D., Allsup, D., Bloor, A. J. C., Sarma, A., Varghese, A. M., Munir, T., & Hillmen, P. Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL (2023)
Journal Article
Visentin, A., Chatzikonstantinou, T., Scarfò, L., Kapetanakis, A., Demosthenous, C., Karakatsoulis, G., ERIC Group, Minga, E., Chamou, D., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M., Baliakas, P., Besikli-Dimou, S., Bron, D., Chatzileontiadou, S., Cordoba, R., Correa, J. G., …Te Raa, D. (2023). The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. American Journal of Hematology, 98(12), 1856-1868. https://doi.org/10.1002/ajh.27093

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytos... Read More about The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide (2023)
Journal Article
Molica, S., Rossi, M., & Allsup, D. (2023). Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide. Acta Haematologica, 147(3), 257-259. https://doi.org/10.1159/000533349

In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus... Read More about Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.